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ABSTRACT
Background: Rituximab (RTX), a monoclonal antibody that selectively binds to CD20+ B 
cells, showed favorable outcomes in patients with idiopathic inflammatory myopathies 
(IIM) in small case series, but the evidence is still not enough. Our goal was to determine the 
efficacy and safety of RTX for Korean patients with refractory IIM.
Methods: We retrospectively analyzed the medical records of 16 patients with refractory 
IIM treated with RTX in seven tertiary rheumatology clinics in the Korea. The efficacy of 
RTX was evaluated with the improvement of serum creatine phosphokinase (CPK) level 
and physician's global assessment (PGA), and daily corticosteroid dose reduction. A > 25% 
decrease in CPK level, corticosteroid dose, or PGA was considered significant. A complete 
response (CR) was designated by meeting three efficacy criteria and a partial response (PR) 
by only two criteria.
Results: Sixteen patients with IIM were evaluated (13 female; median age, 51.8 years). All 
patients had received at least one conventional immunosuppressive agent (median, 3.6 
[2.0–5.0]) and concomitant corticosteroids. The median CPK level and median dose of 
prednisolone was 421.0 units/L and 20.0 mg/day respectively. Eleven patients were treated 
with intravenous immunoglobulin. Seven patients received 2,000 mg of RTX and the others 
received lower dose. Twenty-four weeks after RTX treatment, 11 patients achieved a > 25% 
reduction in corticosteroid dose and CPK levels, and nine showed improved PGA. The overall 
response rate was 68.8% (11 patients). At the end of follow-up (median 24 weeks), 12 (75.0%) 
patients responded overall: four (25.0%) and eight (50.0%) patients achieved CR and PR, 
respectively. Baseline muscle enzyme levels were higher in responders than non-responders, 
but disease duration, RTX dose, ESR and serum CRP were not significantly different between 
the two groups. The rate of adverse event was 25.4/1,000 person-years.
Conclusion: RTX could be an effective and relatively safe therapeutic option in patients with 
refractory IIM.
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INTRODUCTION
Idiopathic inflammatory myopathies (IIM) are a group of rare autoimmune rheumatic 
disease that primarily induces chronic inflammation of skeletal muscles, leading to proximal 
muscle weakness and disability. Patients with IIM generally receive high dose systemic 
glucocorticoids in combination with antimalarial agents or conventional non-targeting 
immunosuppressive,1 but the management of IIM remains challenging for clinicians.
Patients with IIM often experience extensive muscular inflammation, causing difficulty 
in swallowing, voiding, and deterioration of performing activities of daily living. Life-
threatening extra-muscular complications, including interstitial lung disease (ILD), are also 
prevalent. However, a considerable portion of patients inadequately responds to the current 
treatment options. Owing to the rarity and heterogeneity of IIM, clinical trials and evidence 
for guidelines are also insufficient, and the 10-year mortality was still high in recent studies 
(14%–38%).2,3 Although interest in biologic agents that directly target the immune cells 
or cytokines has increased in other systemic rheumatic disease following advances in the 
understanding of the immunopathogenesis, studies that have investigated the efficacy and 
safety of biologic agents in patients with IIM are limited.4
Rituximab (RTX) is a monoclonal antibody that selectively binds to CD20+ B cells.5 RTX 
was originally developed for the treatment of lymphoproliferative diseases,6 but it is also 
approved for the treatment of rheumatoid arthritis,7 pemphigus vulgaris,8 granulomatosis 
with polyangiitis (GPA), and microscopic polyangiitis (MPA).9 In addition, it is used widely 
to manage a variety of immune-related disorders, including idiopathic thrombocytopenic 
purpura,10 systemic lupus erythematosus,11,12 and multiple sclerosis.13 In terms of IIM, RTX 
also has been believed to be a potential therapeutic option along with the B cell infiltration in 
the muscles of patients with IIM and myositis-associated antibodies (MAA).1,14 RTX showed 
favorable outcomes in patients with refractory IIM who failed to respond to corticosteroid 
and conventional immunosuppressive agents, but most studies were case series and open 
label studies. In Korea, a case series described four patients with refractory IIM treated with 
RTX and all patients responded to IIM.15 Therefore, this paper aimed to identify the efficacy 
and safety of RTX for patients with refractory IIM.
METHODS
Study population
We conducted a retrospective multicenter study of 16 patients with refractory IIM who 
were treated with RTX from July 2006 to October 2017. This multicenter retrospective study 
comprised patients from seven tertiary rheumatology clinics that had obtained official 
endorsement for the use of RTX for refractory IIM from the Ministry of Health and Welfare 
and the Health Insurance Review & Assessment Service (HIRA). Off-label RTX use must be 
officially allowed by each hospital after receiving institutional review board approval and 
submission to the HIRA, because RTX currently is not approved by the Korean Ministry of 
Food and Drug Safety (MFDS) for the treatment of IIMs.
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The medical records of patients with a diagnosis of possible or definite IIM according to 
Bohan and Peter's criteria16,17 and treated with RTX were respectively reviewed. Patients 
with a shorter than 6 months' observation period (from RTX administration to the data 
collection), whose age at diagnosis of IIM was less 16 years of age, and patients with 
malignancy were excluded. RTX was prescribed by expert rheumatologists due to an 
inadequate response or intolerance to corticosteroids and conventional immunosuppressive 
therapy. All patients received RTX intravenously, and the RTX dosing and cycle differed 
depending on the decision of the rheumatologist.
Patient assessment and response criteria
Demographic characteristics, including age (years), sex (female/male), height (cm), and 
weight (kilograms) were recorded. Disease-specific variables, including IIM duration, 
concomitant and cumulative immunosuppressive agent history, IIM activity, the reason 
for RTX administration, and RTX dose and interval, were also assessed at the time of RTX 
administration. The IIM activity was measured by muscle weakness (grade), extra-muscular 
symptoms (skin rash, skin necrosis, dysphagia, dyspnea, Raynaud phenomenon, and ILD), 
constitutional symptoms (fever, fatigue, and weight loss), and laboratory markers including 
muscle enzymes levels (serum creatine phosphokinase [CPK], lactate dehydrogenase [LDH], 
aldolase, aspartate aminotransferase [AST], alanine transaminase [ALT]), complete blood 
count, erythrocyte sedimentation rate (ESR), and C reactive protein (CRP). IIM activity was 
assessed in each hospital and at baseline and followed up at the regular clinical visit schedule 
(2- or 4-week intervals). The reference ranges and units for laboratory markers were similar 
among the 7 rheumatology clinics.
We assessed the efficacy of RTX based on the serum CPK level, daily dose of corticosteroid 
and opinion of the physician.18 A decrease in CPK level and daily corticosteroid dose was 
considered to be significant if it was > 25% of the baseline. The physician's opinion on the 
response was dichotomized to “response” or “no response.” Complete response (CR) and 
partial response (PR) were defined as a patient meeting all three or only two efficacy criteria, 
respectively. Three patients were administered a second cycle of RTX after completion of the 
first cycle of RTX administration but the response was assessed based on the first cycle of 
RTX administration.
Statistical analysis
The general statistics of the study population are presented medians (first interquartile, third 
interquartile) for continuous variables, and frequencies with percentage (%) for categorical 
variables. Demographic and clinical characteristics were compared by using Fisher's exact 
test (binary variables) and the Mann-Whitney U test (linear variables). All statistical analyses 
were conducted using IBM SPSS version 25.0 (IBM Corp., Armonk, NY, USA). P values of < 
0.05 (two-tailed) were considered statistically significant.
Ethics statement
This study was approved by the institutional review board (IRB) of each hospital and the 
requirement for informed consent was waived because of the retrospective nature of the study 
(IRB No. HYUH 2018-01-020-002 in Hanyang University Hospital, AJIRB-MED-OBS-17-509 
in Ajou University Hospital, 2018-0567 in Asan Medical Center, 2018-0541-001 in Severance 
Hospital, Yonsei University Health System, 2018-02-027 in Chungnam National University 
Hospital, KUH1010916 in Konkuk University Medical Center, CNUH-2018-058 in Chonnam 
National University Hospital).
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RESULTS
Demographic and clinical characteristics
The baseline demographic and clinical characteristics are presented in Table 1. Ten patients with 
dermatomyositis and six patients with polymyositis were treated with RTX. Thirteen (81.3%) 
were female, the median age at RTX treatment was 51.8 (42.5–59.0) years of age, and the median 
IIM disease duration (from IIM diagnosis to RTX treatment) was 88.4 (24.3–162.8) months. 
All patients had insufficient response or intolerance to at least one (median, 3.6 [2.0–5.0]) 
conventional immunosuppressive agent: azathioprine, n = 12, 75.0%; methotrexate, n = 11, 
68.8%; mycophenolate mofetil, n = 10, 63.0%; hydroxychloroquine, n = 8, 50.0%; cyclosporine, 
n = 5, 31.3%; cyclophosphamide, n = 5, 31.3%; tacrolimus, n = 5, 31.3%; leflunomide, n = 1, 
6.3%). Twelve (75.0%) patients had received intravenous immunoglobulin therapy.
IIM activity at the time of RTX treatment is summarized in Table 2. Most patients (n = 14,  
87.5%) experienced muscle weakness and all patients had at least one extra-muscular 
manifestation (dermatomyositis specific skin rash, n = 8, 50.0%; ILD, n = 5, 31.3%; 
dysphagia, n = 4, 25.0%; arthritis, n = 4, 25%). Eight (50%) patients had constitutional 
manifestations, such as fatigue (n = 6, 37.5%), fever (n = 3, 18.8%), and weight loss (n = 3,  
18.8%). The median serum CPK level was 421.0 (67.8–937.0) unit/L and the median 
corticosteroid dose was 20.0 (15.0–45.0) mg (prednisone equivalent dose) (Table 2).
RTX administration and treatment response
Six (37.5%) patients received two doses of 1,000 mg RTX 2 weeks apart (total 2 g), 4 (25.0%) 
patients received two doses of 500 mg RTX 2 weeks apart (total 1 g), 3 (18.8%) patients 
received a single dose of 1,000 mg, one patient received 500 mg weekly for a total of four 
doses (total 2 g), 1 patient received 600 mg RTX 2 weeks apart (total 1.2 g), and one patient 
received a single dose of 200 mg RTX (Table 1).
The response rate to RTX treatment is shown in Fig. 1. At 12 weeks after RTX treatment, 11 
(68.8%) and 9 (56.3%) patients achieved a 25% reduction in CPK and daily corticosteroid, 
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Table 1. Clinical characteristics of 16 patients with idiopathic inflammatory myopathies treated with RTX
No. Sex Age, yr Disease 
duration, mon
Diagnosis Previous treatment Concomitant 
treatment
RTX dose, mg RTX cycles Responsea
1 F 56 187 DM AZA, Cys, TAC, HCQ, IVIG MTX, MMF 500 × 2 1 Y
2 F 54 169 DM MTX, MMF, Cys, TAC, CYC, LEF, HCQ, IVIG AZA 1,000 × 2 2 N
3 F 42 37 DM MTX, AZA, TAC, IVIG MMF, HCQ 500 × 2 1 N
4 M 59 20 DM AZA, Cys, CYC, HCQ MMF 500 × 2 1 Y
5 F 53 57 DM HCQ, IVIG MMF 1,000 × 2 2 N
6 F 33 186 PM AZA, CYC, IVIG MMF, MTX 500 × 2 2 Y
7 F 38 99 PM AZA, IVIG MTX 1,000 × 2 1 Y
8 F 57 13 DM CYC, HCQ, IVIG AZA 200 × 1 1 Y
9 F 63 84 PM CYC, IVIG AZA 500 × 4 1 Y
10 M 66 14 PM MMF, IVIG AZA 600 × 2 1 Y
11 F 41 171 DM AZA, MMF, Cys, IVIG 1,000 × 2 1 Y
12 F 57 62 DM MTX, AZA TAC 1,000 × 2 1 Y
13 F 44 70 PM MTX, AZA, MMF, TAC, IVIG MTX 1,000 × 2 1 Y
14 F 59 96 DM HCQ HCQ 1,000 × 1 1 N
15 F 45 144 PM MTX, AZA, MMF, Cys, TAC, IVIG 1,000 × 1 1 N
16 M 62 6 DM HCQ MTX 1,000 × 1 1 Y
DM = dermatomyositis, AZA = azathioprine, Cys = cyclosporin, TAC = tacrolimus, HCQ = hydroxychloroquine, IVIG = intravenous immunoglobulin, MTX = 
methotrexate, MMF = mycophenolate mofetil, PM = polymyositis, RTX = rituximab.
aClinical response at 24 weeks after RTX infusion.
respectively, and 6 (37.5%) patients showed improved physician's global assessment (PGA). 
CR and PR were achieved by 2 and 6 patients, respectively, and the overall response rate was 
62.5% (10 patients).
At 24 weeks after RTX treatment, 11 (68.8%) patients achieved a 25% reduction in 
corticosteroid dose and CPK levels and 9 (56.3%) showed improved PGA. CR was achieved by 
4 (25.0%) patients, and the overall response rate was 68.8% (11 patients). The median serum 
CPK level decreased from 421.5 (67.8–973.0) to 42.0 (interquartile range [IQR], 15.5–222.0) and 
the median dose of corticosteroid decreased from 20 mg/day (IQR, 15–45.0) to 13.8 mg (IQR, 
10.6–15.2). At the end of follow-up (median 24 weeks, range 24–68 weeks), the overall response 
was 12 (75.0%) patients: 4 (25.0%) and 8 (50.0%) patients achieved CR and PR, respectively.
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Table 2. Myositis activity at the time of rituximab treatment
Variables Values
Combined clinical manifestations
Muscle weakness 14 (87.5)
Myalgia 11 (68.8)






Weight loss 3 (18.8)
Dyspnea 3 (18.8)







ESR, mm/hr 20.5 (7.8–61.0)
CRP, mg/L 3.5 (1.9–4.3)
Daily corticosteroid dosage, mg, PDS equivalent dose 20.0 (15.0–45.0)
Values are given as median (interquartile range) or number (%).
ILD = interstitial lung disease, CPK = creatine phosphokinase, LDH = lactate dehydrogenase, ESR = erythrocyte 




















Complete response Partial response
PDS reduction > 25% CPK reduction > 25% PGA improvement
Fig. 1. Response rate of RTX treatment. 
CPK = creatine phosphokinase, PGA = physician's global assessment, PDS = prednisolone, RTX = rituximab.
Three patients were re-administered RTX after completion of the first cycle of RTX 
administration (at intervals of 27, 30, and 52 weeks) when IIM relapsed or was clinically 
indicated. Two patients were assessed to have no response in both the first and second cycles.
Factors associated with response to RTX treatment
A comparison between responders and non-responders at 24 weeks after RTX treatment is 
shown in Table 3. Baseline median muscle enzyme levels were higher in responders than 
non-responders: serum CPK, 692.0 vs. 64.0, P = 0.013; LDH, 530.0 vs. 286.0, P = 0.013; and 
aldolase, 18.1 vs. 6.7, P = 0.013. All patients with baseline serum CPK over 400 responded to 
treatment, but 2 out of 3 patients with CPK between 100 and 400, and only 1 out of 5 patients 
with CPK below 100 responded to RTX treatment. However, all other demographic and 
clinical characteristics, including patient age, sex, disease subtype, disease duration, RTX 
dose, ESR, and serum CRP, were not significantly different between the two groups.
We investigated autoantibody patterns and treatment response. Of the 16 patients, 10 
patients tested ANA at the time of RTX administration, and ANA was detected in 6 patients. 
The speckled pattern was the most common ANA pattern (4 out of 6 patients), followed by 
mixed and cytoplasmic patterns (1 patient each). All the 6 ANA–positive patients responded 
to RTX treatment (including all the 4 cases of CR), while only 2 cases achieved PR and the 
other 2 cases did not respond to RTX treatment among the 4 ANA-negative patients. Anti Jo-1 
antibody was tested for in 3 patients and detected in 2 patients. All the 3 patients who tested 
positive for anti Jo-1 antibody achieved CR.
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Table 3. Comparison between responders and non-responders at 24 weeks after RTX treatment
Variables at baseline Responders (n = 11) Non-responders (n = 5) P value
Age, yr 52.4 ± 11.3 50.6 ± 7.0 0.583
Disease duration 82.9 ± 70.4 100.6 ± 56.0 0.743
BMI 22.8 ± 4.3 23.6 ± 4.9 1.000
RTX dose/BSA 813.6 ± 339.3 890.0 ± 309.2 0.859
Daily corticosteroid 20.0 (15.0–37.5) 30.0 (20.0–30.0) 0.228
CPK 692.0 (363.0–1,104.0) 64.0 (63.0–79.0) 0.013
LDH 530.0 (405.0–599.0) 286.0 (258.0–309.0) 0.013
Aldolase 18.1 (15.9–22.3) 6.7 (6.7–8.3) 0.016
ESR 22.9 ± 20.1 54.0 ± 43.7 0.298
CRP 0.3 (0.2–0.4) 0.4 (0.3–0.4) 0.544
Sex 0.509
Male (n = 3) 3 (100.0) 0 (0.0)
Female (n = 13) 8 (61.5) 5 (38.5)
Disease subtype 0.588
DM (n = 10) 6 (60.0) 4 (40.0)
PM (n = 6) 5 (83.3) 1 (16.7)
Disease duration, yr 1.000
< 5 (n = 6) 4 (66.7) 2 (33.3)
5–10 (n = 5) 4 (80.0) 1 (20.0)
> 10 (n = 5) 3 (60.0) 2 (40.0)
Dose of RTX 1.000
Less than 2 g (n = 11) 7 (70.0) 3 (30.0)
2 g (n = 5) 4 (66.7) 2 (33.3)
Values are given as mean (standard deviation), median (interquartile rage) or number (%).
Normality was tested using Shapiro-Wilk normality test.
RTX = rituximab, BMI = body mass index, BSA = body surface area, CPK = creatine phosphokinase, LDH = lactate 
dehydrogenase, ESR = erythrocyte sedimentation rate, CRP = C-reactive protein, DM = cermatomyositis, PM = 
polymyositis.
Safety of RTX
In the 39.3 person-years of the observation period, we observed one adverse event (AE) (rate 
= 25.4/1,000 person-years). One patient developed upper respiratory tract infection, but 
hospitalization was not required. No severe adverse event (SAE) or infusion reaction occurred.
DISCUSSION
In this multicenter study, RTX was effective in 75% of patients (12/16) at a median of 24 weeks 
after treatment for patients with refractory IIM who had responded poorly to conventional 
immunosuppressant treatment. The serum CPK level and daily dose of corticosteroid 
decreased significantly compared with the baseline after RTX in most patients, suggesting 
the clinical efficacy and safety of RTX in patients with refractory IIM.
Since the first classification criteria and 5 subsets for IIM were provided by Bohan and Peter17 
in 1975, extended understanding and more clinical subsets of IIM have been suggested. 
However, unlike the simple terminology “myopathy,” neither the pathophysiology nor 
phenotype of patients with IIM are straightforward. It is important to note that the diagnosis 
of IIM may be challenging, as the diagnosis of IIM should be made circumspectly after the 
exclusion of a variety of diseases that mimic IIM.19,20 Patient assessment also is complicated. 
The pattern and severity of organ involvement is highly heterogeneous in each patient, 
and an objective measurement of muscular and extra-muscular involvement is complex. 
Given the rarity and heterogeneity of IIM,19-21 outcome measure and response criteria 
have been available only in recent years, and evidence level for IIM treatment strategy is 
low. Unfortunately, a meaningful portion of patients with IIM responds incompletely to 
conventional immunosuppressive agents; therefore, patients with refractory IIM may be 
subjected to therapeutic strategies that have not been sufficiently investigated.
RTX, a selective CD20+ B lymphocyte-depleting agent, is a potential therapeutic option for 
the IIM treatment with evidence of prominent B lymphocyte infiltration in the muscles of 
patients with IIM. Infiltration of cytotoxic CD8+ T lymphocytes at the endomysium and/
or that of B lymphocytes accompanied by CD4+ T lymphocytes at perivascular sites are the 
pathologic hallmark of IIM.22,23 Although earlier studies suggested that B lymphocytes were 
considered to be more important in dermatomyositis than in polymyositis,24,25 subsequent 
studies identified the presence of plasma cells and immunoglobulin-transcribing genes in the 
endomysium of patients with polymyositis and inclusion body myositis.26
The strong association between MAA and clinical phenotype also supports the critical 
role of B lymphocytes in the pathophysiology of IIM. Antisynthetase syndrome (ASS) is 
a well-known subtype of IIM, characterized by a progressive disease course with severe 
ILD, mechanic's hand, a distinct histological pattern on muscle tissue, and ASS-specific 
autoantibodies, such as anti-Jo-1 antibody.27 Immune-mediated necrotizing myopathy 
(IMNM) is another particular subtype of IIM, associated with necrosis of microfibers without 
inflammatory cell infiltrates and IMNM-specific antibodies, including anti-3-hydroxy-3-
methylglutaryl CoA reductase antibody and anti-signal recognition protein antibody.28-30 
Anti-melanoma differentiation–associated gene 5 (MDA5) antibody is a novel and specific 
antibody associated with amyopathic dermatomyositis with rapidly progressive ILD.31,32 Anti-
transcription intermediary factor 1γ antibody and the NM fragment of anti-nuclear matrix 
protein antibody have been described as related to cancer-associated myositis.33-35
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Thus, evidence has started to accumulate regarding the efficacy of RTX in the management 
of IIM. A number of case series and small open-label trials have been published, and the 
majority of the studies have described patients with refractory and/or life-threatening IIM. 
There also is a completed randomized, double-blinded, controlled clinical trial in patients 
with IIM (the RTX in myositis [RIM] trial).36 In total, 195 definite or probable patients 
with dermatomyositis or polymyositis or juvenile patients with dermatomyositis with poor 
response to glucocorticoids and at least one immunosuppressive agent were included in 
the RIM trial. Patients were randomly assigned to receive RTX at baseline (RTX early group) 
or 8 weeks later (RTX late group), and the time to achieving the International Myositis 
Assessment and Clinical Studies (IMACS) definition of improvement was compared between 
the two groups.37 At the end of the study (44 weeks after RTX treatment), 82.6% (161/195) 
of the patients met the definition of improvement although early and late treatment of RTX 
showed no significant differences for the primary and secondary end points.
It also is important to emphasize that previous reports show a considerable association 
between the clinical response and presence of MAA. The efficacy of RTX in patients with 
refractory ASS has been reported.38 Levine et al.39 reported that patients with the anti-Jo-1 
antibody had a greater improvement in lung function after RTX treatment, and one recent 
study reported that the serum titer of MAA decreased after B cell depletion and was correlated 
with changes in disease activity.40 Aggarwal et al.41 evaluated predictors for the response 
to RTX from the RIM trial, and revealed that presence of MAA and less IIM-associated 
damage were associated with good prognosis and rapid clinical improvement. In this present 
study, we also revealed that ANA-positivity was associated with better clinical response to 
RTX treatment: all the 4 cases of CR were ANA–positive, while among the 4 ANA-negative 
patients, 2 cases achieved PR and the other 2 cases did not respond to RTX treatment.
When comparing responders and non-responders, ESR and serum CRP levels tended to be 
higher in non-responders (although not statistically significantly), despite the lower CPK 
levels in non-responders. This could be associated with the fact that the improvement in 
extra-muscular involvement was not fully reflected in the current response criteria. There 
were 2 patients who received RTX due to acute aggravation of organizing pneumonia, with 
normal serum CPK level (64 unit/dL and 79 unit/dL, respectively) and high ESR (116 mm/hr 
and 64 mm/hr, respectively). Unlike previous studies42,43 which reported especially favorable 
responses to pulmonary involvement, the 2 patients mentioned above with organizing 
pneumonia did not fully recover after RTX treatment, and they did not achieve CPK reduction 
nor by their physician's opinion. Contrarily, one patient with generalized and refractory skin 
lesions with normal serum CPK (32 unit/dL), CRP (0.15 mg/dL) and ESR levels (18 mm/hr) had 
almost fully recovered after RTX treatment and was classified as a responder. With the brief 
response criteria in this study, the data regarding extra-muscular lesions were simply handled 
by ‘physician's global assessment’, and further studies should apply a standardized assessment 
protocol for extra-muscular involvement such as the 2016 ACR-EULAR response criteria.44
Most of the patients did not receive additional immunosuppressive agents during the 
observational period except one patient who started MTX 6 weeks after RTX administration. Our 
data reveals that the long-term clinical efficacy of RTX may persist, which is similar to previous 
studies,45 whereas reconstitution of peripheral blood B cell lineage occurs within a few months.46
Although this study describes the clinical efficacy of RTX in patients with refractory IIM, 
our study differs from the RIM trial as RTX is not approved for use in Korean patients with 
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IIM and our study is based on real-world data. Participants in our study were older (median, 
51.8 years of age) with a longer disease duration (median, 7.4 years) than those in the RIM 
trial (mean age early forties, mean disease duration 5.3 years). However, the ratio of female 
participants (81%), the number of previous immunosuppressive agents administered prior 
to RTX treatment (median, 3.6), and the daily corticosteroid dose at RTX administration 
(median, 20.0 mg) were similar to that of the RIM trial (71% female patients, mean 3.1 
immunosuppressive agents, approximately 20 mg of daily corticosteroid). The dosing 
regimen for RTX in IIM was also different. In the RIM trial, the dose of RTX used (total 2 g, as 
2 × 1 g infusions) was the same as the FDA-approved dose for RA, GPA, and MPA.
The safety of RTX should also be discussed. We observed only one infection, and no SAE 
or infusion reaction occurred in this study; the rate of AEs in this study is lower than that 
of other studies. In a study that analyzed the efficacy and safety of RTX in Korean patients 
with active lupus nephritis, four out of 39 patients experienced an infusion reaction and 
three patients had an infection.12 In the RIM trial, there were 67 SAEs in 64 patients, and 
the RTX group showed significantly more infusion reactions than the placebo group. This 
underestimation of AE/SAEs may be related to the RTX dose, which was lower than that of 
other studies (less than half the patients received a total of 2 g RTX) and the collection of AE/
SAEs by retrospective chart review.
The relatively small number of study populations, lack of long term outcome and repeated 
treatment, incompletion of the autoantibody data and the lack of MAA and immunological 
data including B lymphocyte count are the limitations of our study.
Despite these limitations, it can be concluded that RTX is an effective and safe therapeutic 
option in patients with refractory IIM who have responded poorly to conventional treatment. 
We believe that this study adds to the current knowledge of RTX in patients with IIM. Further 
prospective studies in Korean patients with IIM are required to provide a rationale for the 
application of RTX in patients with refractory IIM.
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